Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 14 EP applications Gavin James Fowler has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 14, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12725047

COMBINATION COMPRISING UMECLIDINIUM AND A CORTICOSTEROID

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61K 45/06, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12725046

DRY POWDER INHALER COMPOSITIONS COMPRISING UMECLIDINIUM

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61K 45/06, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12766434

SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR

IPC classification:
A61K 31/18, A61K 31/33, C07C 311/21, C07C 311/29, C07D 213/30, C07D 213/38, C07D 213/61, C07D 213/65, C07D 213/68, C07D 213/75, C07D 233/22, C07D 239/28, C07D 249/08, C07D 257/04, C07D 261/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11778236

METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION

IPC classification:
A61K 38/26, A61P 3/10, A61P 9/00, A61P 9/04
Applicant:
GlaxoSmithKline LLC
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13720813

AGGREGATE PARTICLES

IPC classification:
A61K 9/14, A61K 9/16, A61K 31/138, A61K 31/439, A61K 45/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14193184

Multispecific antigen binding proteins targeting HGF

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11785457

MULTISPECIFIC ANTIGEN BINDING PROTEINS TARGETING HGF

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13753596

CHEMICAL PROCESS

IPC classification:
C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13811460

COMBINATION OF UMECLIDINIUM, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE FOR USE IN THE TREATMENT OF INFLAMMATORY OR RESPIRATORY TRACT DISEASES

IPC classification:
A61K 9/00, A61K 9/14, A61K 31/137, A61K 31/439, A61K 31/56, A61K 31/573, A61P 11/00, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14709691

ANTI-LAG-3 BINDING PROTEINS

IPC classification:
C07K 16/28
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14776725

TOPICAL COMPOSITIONS FOR TREATMENT OF EXCESSIVE SWEATING AND METHODS OF USE THEREOF

IPC classification:
A61K 31/439, A61P 17/00, A61Q 15/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP12170402

Muscarinic acetylcholine receptor antagonists

IPC classification:
A61K 31/44, C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
PATENT GRANTED
EP16177012

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/44, C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15726106

FLUTICASONE FUROATE IN THE TREATMENT OF COPD

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61P 11/00, A61P 11/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature